Haag-Streit UK (HS-UK) has announced the immediate availability of Optovue AngioVue Retina (pictured), a proprietary imaging option that provides retina specialists with a non-invasive, dyeless way to quickly visualise blood flow in the retina.
AngioVue Retina is configured with optical coherence tomography (OCT) and OCT angiography (OCT-A). It is designed specifically for retinal practices to allow adoption of OCT and OCT-A into the clinical workflow with minimal disruption.
Optovue’s AngioVue Retina provides retinal specialists with the ability to quickly visualise the presence or absence of retinal vessels and assess new information about the microvasculature in detail.
The information may be integrated with other diagnostic imaging results to form a complete picture of a patient’s disease state and their treatment options.
Optovue’s senior vice president of global sales, John Hawley, said, “By adding AngioVue Retina to our product portfolio, we are able to help retinal specialists acquire OCT-A technology in a cost-efficient manner, thereby adding this technology to their armamentarium of diagnostic imaging tools.”
Mr Hawley added: “OCT-A imaging is in its nascent phase and we expect applications to rapidly unfold over the next few years. As such, we are pleased to offer this important technology in different product configurations that meet the needs of all ophthalmology practices.”
The company also announced its new DualTrac Motion Correction for use with both AngioVue and AngioVue Retina, a two-level approach to correcting motion artifacts resulting from patient movement.
The first level provides real-time correction for rapid eye movements, blinking or eye drifting. The second level occurs during imaging post-processing and corrects smaller levels of motion distortion.
The combined approach is said by the company to result in robust motion correction for patients who have trouble directing their focus on a central point during an eye examination, which is essential for high-quality OCT-A imaging.
For more information, visit the Haag-Streit website.